Drug Trial Radar · NCT04838444
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
363
Actual
Start
Apr 2, 2021
Primary completion
Mar 3, 2023
Study completion May 2031
Sponsor
- Lead sponsor
- Valneva Austria GmbHIndustry
- Sponsor type
- Industry
- First posted
- Apr 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
Conditions
- Chikungunya Virus Infection
Interventions
VLA1553Biological
Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With Seroresponse Levels Post-vaccination. (Defined as µPRNT50 ≥150)Time frame: Year 2
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Accelerated Enrollment Solutions (AES)
Phoenix, Arizona
Velocity Clinical Research
Hallandale, Florida
Accelerated Enrollment Solutions (AES)
Chicago, Illinois
Alliance for Multispecialty Research (AMR)
Lexington, Kentucky
Velocity Clinical Research
Grand Island, Nebraska
Velocity Clinical Research
Omaha, Nebraska
Alliance for Multispecialty Research (AMR)
Knoxville, Tennessee
Velocity Clinical Research
Austin, Texas
Velocity Clinical Research
West Jordan, Utah
Allliance for Multispecialty Research (AMR)
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.